Cyclopharm Limited

ASX:CYC Stock Report

Market Cap: AU$176.2m

Cyclopharm Future Growth

Future criteria checks 5/6

Cyclopharm is forecast to grow earnings and revenue by 104.9% and 42.7% per annum respectively. EPS is expected to grow by 104.3% per annum. Return on equity is forecast to be 13.2% in 3 years.

Key information

104.9%

Earnings growth rate

104.3%

EPS growth rate

Medical Equipment earnings growth16.1%
Revenue growth rate42.7%
Future return on equity13.2%
Analyst coverage

Low

Last updated27 Aug 2024

Recent future growth updates

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Apr 18
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Mar 31
Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Oct 17
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Jun 09
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Mar 06
Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02
Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22
We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29
Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27
Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01
Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07
Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02
Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06
We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Earnings and Revenue Growth Forecasts

ASX:CYC - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202667119131
12/31/202547-2-211
12/31/202428-11-13-121
6/30/202424-9-13-12N/A
3/31/202426-7-10-10N/A
12/31/202327-5-8-7N/A
9/30/202329-6-8-7N/A
6/30/202330-7-8-7N/A
3/31/202327-7-8-7N/A
12/31/202225-7-8-7N/A
9/30/202224-5-6-4N/A
6/30/202223-4-4-2N/A
3/31/202221-4-3-2N/A
12/31/202120-5-3-2N/A
9/30/202120-5-5-4N/A
6/30/202120-4-7-6N/A
3/31/202119-5-8-8N/A
12/31/202018-6-9-9N/A
9/30/202017-6-7-7N/A
6/30/202016-6-6-5N/A
3/31/202017-4-3-3N/A
12/31/201917-3-10N/A
9/30/201916-3-10N/A
6/30/201916-2-10N/A
3/31/201916-1-1-1N/A
12/31/2018160-2-1N/A
9/30/2018160-2-1N/A
6/30/201816-1-10N/A
3/31/201816-1N/A0N/A
12/31/201716-2N/A-1N/A
9/30/201715-1N/A0N/A
6/30/201714-1N/A0N/A
3/31/2017150N/A0N/A
12/31/2016151N/A1N/A
9/30/2016143N/A2N/A
6/30/2016145N/A4N/A
3/31/2016135N/A4N/A
12/31/2015135N/A4N/A
9/30/2015124N/A4N/A
6/30/2015113N/A4N/A
3/31/2015114N/A4N/A
12/31/2014124N/A4N/A
9/30/201413-2N/A3N/A
6/30/201414-8N/A2N/A
3/31/201413-9N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CYC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYC is expected to become profitable in the next 3 years.

Revenue vs Market: CYC's revenue (42.7% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: CYC's revenue (42.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CYC's Return on Equity is forecast to be low in 3 years time (13.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 07:11
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclopharm Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Sarah MannMA Moelis Australia Securities Pty Ltd